Short Interest in Briacell Therap (NASDAQ:BCTX) Increases By 223.7%

Briacell Therap (NASDAQ:BCTX) was the recipient of a significant increase in short interest in January. As of January 30th, there was short interest totaling 142,140 shares, an increase of 223.7% from the January 15th total of 43,910 shares. Approximately 2.1% of the shares of the stock are short sold. Based on an average daily trading volume, of 649,735 shares, the short-interest ratio is presently 0.2 days. Based on an average daily trading volume, of 649,735 shares, the short-interest ratio is presently 0.2 days. Approximately 2.1% of the shares of the stock are short sold.

Hedge Funds Weigh In On Briacell Therap

A hedge fund recently bought a new stake in Briacell Therap stock. Citadel Advisors LLC acquired a new position in Briacell Therap (NASDAQ:BCTX) in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 11,055 shares of the company’s stock, valued at approximately $122,000. Citadel Advisors LLC owned 1.63% of Briacell Therap as of its most recent SEC filing. Institutional investors and hedge funds own 15.42% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Briacell Therap in a research note on Wednesday, January 21st. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, Briacell Therap has a consensus rating of “Hold” and an average price target of $320.00.

Briacell Therap Price Performance

Shares of Briacell Therap stock opened at $4.09 on Friday. The firm has a market cap of $29.65 million, a P/E ratio of -0.09 and a beta of 1.42. The firm has a 50 day simple moving average of $6.80 and a 200 day simple moving average of $8.62. Briacell Therap has a fifty-two week low of $4.01 and a fifty-two week high of $98.20.

Briacell Therap (NASDAQ:BCTX) last posted its quarterly earnings data on Monday, December 15th. The company reported ($4.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($12.11) by $7.76. On average, sell-side analysts expect that Briacell Therap will post -2.45 EPS for the current year.

About Briacell Therap

BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers.